- Home
- REGN vs COP Comparison
REGN vs COP Comparison
Compare REGN & COP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- COP
- Stock Information
- Founded
- REGN 1988
- COP 1917
- Country
- REGN United States
- COP United States
- Employees
- REGN N/A
- COP N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- COP Integrated oil Companies
- Sector
- REGN Health Care
- COP Energy
- Exchange
- REGN Nasdaq
- COP Nasdaq
- Market Cap
- REGN 63.4B
- COP 110.7B
- IPO Year
- REGN 1991
- COP N/A
- Fundamental
- Price
- REGN $547.67
- COP $88.86
- Analyst Decision
- REGN Buy
- COP Buy
- Analyst Count
- REGN 23
- COP 17
- Target Price
- REGN $907.39
- COP $124.44
- AVG Volume (30 Days)
- REGN 1.2M
- COP 7.6M
- Earning Date
- REGN 04-29-2025
- COP 05-08-2025
- Dividend Yield
- REGN 0.32%
- COP 3.51%
- EPS Growth
- REGN 16.49
- COP N/A
- EPS
- REGN 39.43
- COP 7.91
- Revenue
- REGN $14,085,700,000.00
- COP $59,075,000,000.00
- Revenue This Year
- REGN $2.38
- COP $7.62
- Revenue Next Year
- REGN $7.65
- COP $2.90
- P/E Ratio
- REGN $14.23
- COP $11.23
- Revenue Growth
- REGN 7.52
- COP N/A
- 52 Week Low
- REGN $520.50
- COP $79.88
- 52 Week High
- REGN $1,211.20
- COP $124.23
- Technical
- Relative Strength Index (RSI)
- REGN 38.69
- COP 45.59
- Support Level
- REGN $542.44
- COP $86.88
- Resistance Level
- REGN $615.61
- COP $92.44
- Average True Range (ATR)
- REGN 22.06
- COP 2.28
- MACD
- REGN -0.13
- COP 0.14
- Stochastic Oscillator
- REGN 28.57
- COP 36.09
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.